NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.59 -0.02 (-1.24 %)
(As of 05/27/2018 10:05 AM ET)
Previous Close$1.59
Today's Range$1.56 - $1.6110
52-Week Range$1.09 - $3.78
Volume125,240 shs
Average Volume174,004 shs
Market Capitalization$46.17 million
P/E Ratio-1.26
Dividend YieldN/A
Beta0.7

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio3.40
Quick Ratio3.40

Price-To-Earnings

Trailing P/E Ratio-1.26
Forward P/E Ratio-1.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales92.32
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book3.53

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-27,360,000.00
Net MarginsN/A
Return on Equity-175.32%
Return on Assets-120.22%

Miscellaneous

Employees36
Outstanding Shares29,030,000

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.06. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

6 equities research analysts have issued 1 year target prices for Catabasis Pharmaceuticals' stock. Their predictions range from $2.00 to $9.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $5.6667 in the next twelve months. View Analyst Ratings for Catabasis Pharmaceuticals.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne Ph.D., Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Andrew J. Nichols Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
  • Dr. Michael Jirousek Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 59)
  • Ms. Deirdre A. Cunnane, Chief Legal Officer (Age 53)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News stories about CATB stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CLARUS LIFESCIENCES II, L.P. (6.97%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $1.59.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $46.17 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (CATB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catabasis Pharmaceuticals (NASDAQ:CATB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Catabasis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.6667, suggesting that the stock has a possible upside of 256.39%. The high price target for CATB is $9.00 and the low price target for CATB is $2.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.6667$5.6667$5.3333$5.3333
Price Target Upside: 256.39% upside187.65% upside241.88% upside229.22% upside

Catabasis Pharmaceuticals (NASDAQ:CATB) Consensus Price Target History

Price Target History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ:CATB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2018WedbushBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.00LowView Rating Details
11/20/2017CitigroupUpgradeNeutral ➝ Buy$3.00N/AView Rating Details
10/6/2017CowenReiterated RatingMarket Perform$2.00N/AView Rating Details
10/5/2017CIBCReiterated RatingOutperform ➝ Outperform$4.00 ➝ $7.00N/AView Rating Details
10/5/2017OppenheimerBoost Price TargetOutperform$4.00 ➝ $7.00N/AView Rating Details
8/14/2017HC WainwrightBoost Price TargetBuy$8.00 ➝ $9.00MediumView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Catabasis Pharmaceuticals (NASDAQ:CATB) Earnings History and Estimates Chart

Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ:CATB) Earnings Estimates

2018 EPS Consensus Estimate: ($0.87)
2019 EPS Consensus Estimate: ($1.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20182($0.24)($0.23)($0.24)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.20)($0.20)($0.20)
Q1 20191($0.23)($0.23)($0.23)
Q2 20191($0.29)($0.29)($0.29)
Q3 20191($0.34)($0.34)($0.34)
Q4 20191($0.34)($0.34)($0.34)

Catabasis Pharmaceuticals (NASDAQ CATB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($0.23)N/AView Earnings Details
5/10/2018Q1 2018($0.23)($0.29)ViewN/AView Earnings Details
3/15/2018Q4 2017($0.31)($0.24)$0.25 million$0.25 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.33)($0.31)$0.25 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.40)($0.3210)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.45)($0.41)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.49)($0.47)ViewN/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/2/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
8/13/2015Q2 2015($0.70)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Catabasis Pharmaceuticals (NASDAQ:CATB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 32.30%
Institutional Ownership Percentage: 26.81%
Insider Trading History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Trading History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ CATB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catabasis Pharmaceuticals (NASDAQ CATB) News Headlines

Source:
DateHeadline
 Brokerages Expect Catabasis Pharmaceuticals Inc (CATB) to Post -$0.24 Earnings Per Share Brokerages Expect Catabasis Pharmaceuticals Inc (CATB) to Post -$0.24 Earnings Per Share
www.americanbankingnews.com - May 14 at 9:35 AM
Catabasis Pharmaceuticals (CATB) Downgraded by Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 11 at 6:49 PM
BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29
www.reuters.com - May 11 at 5:58 PM
Catabasis Pharmaceuticals (CATB) Issues Quarterly  Earnings ResultsCatabasis Pharmaceuticals (CATB) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 4:17 PM
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares UpEndocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
finance.yahoo.com - May 11 at 8:27 AM
Catabasis Pharmaceuticals: 1Q Earnings SnapshotCatabasis Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:57 PM
Catabasis Pharmaceuticals: Elucidating Edasalonexents Stellar Prospects In DMDCatabasis Pharmaceuticals: Elucidating Edasalonexent's Stellar Prospects In DMD
seekingalpha.com - May 10 at 5:57 PM
Catabasis Pharmaceuticals (CATB) CEO Jill Milne on Q1 2018 Results - Earnings Call TranscriptCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:57 PM
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business ProgressCatabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
finance.yahoo.com - May 10 at 8:24 AM
Does Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB) Past Performance Indicate A Stronger Future?Does Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB) Past Performance Indicate A Stronger Future?
finance.yahoo.com - May 9 at 5:34 PM
Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - May 9 at 8:19 AM
Catabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by BrokeragesCatabasis Pharmaceuticals Inc (CATB) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 6 at 10:26 AM
Catabasis Pharmaceuticals (CATB) Upgraded by ValuEngine to SellCatabasis Pharmaceuticals (CATB) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 3 at 10:05 PM
Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10
finance.yahoo.com - May 3 at 8:16 AM
Catabasis Pharmaceuticals (CATB) Scheduled to Post Earnings on WednesdayCatabasis Pharmaceuticals (CATB) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:32 AM
Catabasis Pharmaceuticals Inc (CATB) Expected to Announce Earnings of -$0.23 Per ShareCatabasis Pharmaceuticals Inc (CATB) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 26 at 9:20 PM
Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular ...Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular ...
www.businesswire.com - April 26 at 8:17 AM
BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent DataBRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data
www.reuters.com - April 26 at 8:17 AM
Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of TreatmentCatabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment
finance.yahoo.com - April 25 at 5:29 PM
Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy?
www.zacks.com - April 25 at 8:20 AM
Q2 2018 Earnings Estimate for Catabasis Pharmaceuticals Inc Issued By Wedbush (CATB)Q2 2018 Earnings Estimate for Catabasis Pharmaceuticals Inc Issued By Wedbush (CATB)
www.americanbankingnews.com - April 23 at 1:52 AM
Wedbush Comments on Catabasis Pharmaceuticals Incs Q1 2019 Earnings (CATB)Wedbush Comments on Catabasis Pharmaceuticals Inc's Q1 2019 Earnings (CATB)
www.americanbankingnews.com - April 20 at 8:36 AM
Catabasis Pharma (CATB) to Reduce Workforce by 42% as Part of RestructuringCatabasis Pharma (CATB) to Reduce Workforce by 42% as Part of Restructuring
www.streetinsider.com - April 20 at 8:24 AM
Alkermes Rallies as FDA Accepts NDA for Depression DrugAlkermes Rallies as FDA Accepts NDA for Depression Drug
finance.yahoo.com - April 18 at 8:16 AM
Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual MeetingCatabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting
finance.yahoo.com - April 18 at 8:16 AM
Alnylam (ALNY) Reports Positive Data for RNAi CandidateAlnylam (ALNY) Reports Positive Data for RNAi Candidate
finance.yahoo.com - April 18 at 8:16 AM
Catabasis to cut workforce 42% in restructuring move; shares down 6% after hoursCatabasis to cut workforce 42% in restructuring move; shares down 6% after hours
seekingalpha.com - April 17 at 5:54 PM
Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular DystrophyCatabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - April 17 at 5:54 PM
Heres Why Geron Stock Surged More Than 90% in 6 MonthsHere's Why Geron Stock Surged More Than 90% in 6 Months
www.nasdaq.com - April 15 at 6:36 PM
Catabasis Pharmaceuticals Inc (CATB) Given Average Rating of "Buy" by AnalystsCatabasis Pharmaceuticals Inc (CATB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 11 at 8:06 AM
Zacks: Brokerages Expect Catabasis Pharmaceuticals Inc (CATB) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Catabasis Pharmaceuticals Inc (CATB) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - April 9 at 11:16 PM
Catabasis Pharmaceuticals (CATB) versus Capricor Therapeutics (CAPR) Head to Head SurveyCatabasis Pharmaceuticals (CATB) versus Capricor Therapeutics (CAPR) Head to Head Survey
www.americanbankingnews.com - April 8 at 5:29 AM
Catabasis Pharmaceuticals Inc (CATB) Expected to Post Earnings of -$0.23 Per ShareCatabasis Pharmaceuticals Inc (CATB) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 23 at 11:14 PM
Wired News – FDA Permitted a Single Registration Trial Assessing Eiger BioPharma’s Lonafarnib in HDV to Support NDA FilingWired News – FDA Permitted a Single Registration Trial Assessing Eiger BioPharma’s Lonafarnib in HDV to Support NDA Filing
finance.yahoo.com - March 23 at 8:18 AM
Wedbush Analysts Boost Earnings Estimates for Catabasis Pharmaceuticals Inc (CATB)Wedbush Analysts Boost Earnings Estimates for Catabasis Pharmaceuticals Inc (CATB)
www.americanbankingnews.com - March 22 at 9:24 AM
FY2022 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Cut by WedbushFY2022 EPS Estimates for Catabasis Pharmaceuticals Inc (CATB) Cut by Wedbush
www.americanbankingnews.com - March 21 at 4:40 PM
Catabasis Pharmaceuticals (CATB) Rating Increased to Buy at Zacks Investment ResearchCatabasis Pharmaceuticals (CATB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
Catabasis Pharmaceuticals (CATB) PT Raised to $6.00 at WedbushCatabasis Pharmaceuticals (CATB) PT Raised to $6.00 at Wedbush
www.americanbankingnews.com - March 20 at 11:31 AM
Catabasis Pharmaceuticals to Present at Oppenheimers 28 - Business Wire (press release)Catabasis Pharmaceuticals to Present at Oppenheimer's 28 - Business Wire (press release)
www.businesswire.com - March 20 at 8:27 AM
Equities Analysts Set Expectations for Catabasis Pharmaceuticals Incs Q2 2018 Earnings (CATB)Equities Analysts Set Expectations for Catabasis Pharmaceuticals Inc's Q2 2018 Earnings (CATB)
www.americanbankingnews.com - March 19 at 2:46 AM
Catabasis Pharmaceuticals Inc (CATB) Receives Consensus Recommendation of "Buy" from BrokeragesCatabasis Pharmaceuticals Inc (CATB) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 9:18 AM
Edited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 6:29 PM
Catabasis Pharmaceuticals (CATB) Announces Quarterly  Earnings ResultsCatabasis Pharmaceuticals (CATB) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 9:28 AM
Catabasis Pharmaceuticals (CATB) CEO Jill Milne on Q4 2017 ... - Seeking AlphaCatabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q4 2017 ... - Seeking Alpha
seekingalpha.com - March 16 at 8:19 AM
Catabasis Pharmaceuticals Inc (CATB) Short Interest Down 58.8% in FebruaryCatabasis Pharmaceuticals Inc (CATB) Short Interest Down 58.8% in February
www.americanbankingnews.com - March 13 at 1:40 AM
Catella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM LtdCatella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM Ltd
finance.yahoo.com - March 12 at 9:02 AM
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15
finance.yahoo.com - March 8 at 8:23 AM
Catabasis Pharmaceuticals (CATB) Set to Announce Earnings on WednesdayCatabasis Pharmaceuticals (CATB) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:32 AM
Catabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A ... - Seeking AlphaCatabasis Has The Potential To Provide Edasalonexent As Treatment For The Entire DMD Population Not Just A ... - Seeking Alpha
seekingalpha.com - February 22 at 8:21 AM
Catabasis Pharmaceuticals Inc (CATB) Receives Consensus Rating of "Buy" from BrokeragesCatabasis Pharmaceuticals Inc (CATB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 20 at 2:54 PM

SEC Filings

Catabasis Pharmaceuticals (NASDAQ:CATB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catabasis Pharmaceuticals (NASDAQ:CATB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catabasis Pharmaceuticals (NASDAQ CATB) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.